Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results
November 04, 2024 16:30 ET
|
Interpace Biosciences, Inc.
●Q3 Revenue of $12.3 million; a $3.2M and 35% increase year-over-year ●Q3 Test volume up 26% year over year to record levels ●Q3 Cash collections of $11.3M; a $1.4M and 15% increase...
Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq
October 15, 2024 16:05 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that its Series B Preferred Stock investors, Ampersand...
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
August 01, 2024 16:30 ET
|
Interpace Biosciences, Inc.
●Q2 Revenue of $12.0 million; a $1.0M and 9% increase year-over-year ●Q2 Test volume up 12% year-over-year to record levels ●Q2 Cash collections of $11.0M; a $0.7M and 7% increase year-over-year ●Q2...
Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
July 29, 2024 08:25 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the undefined...
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
May 09, 2024 16:01 ET
|
Interpace Biosciences, Inc.
●Q1 Revenue of $10.3 million; a 4% increase year-over-year ●Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc....
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
March 07, 2024 08:00 ET
|
Interpace Biosciences, Inc.
●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income from Continuing Operations of $0.8 million and $1.1 million; a $7.0 million and...
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
November 08, 2023 15:29 ET
|
Interpace Biosciences, Inc.
●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and...
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
August 09, 2023 12:30 ET
|
Interpace Biosciences, Inc.
●Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history ●Q2 Test volume up 15% year over year to record levels ●Q2 Reimbursement improvement up 34% year-over-year...
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement
July 10, 2023 15:59 ET
|
Interpace Biosciences, Inc.
Q2 Revenue of $11 million; a 49.1% increase year-over-year and 12.2% better than Q1; highest quarter in history1st Half Revenue $20.9 million; 36.1% improvement over 1st Half 2022Q2 Test volume up...
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023
June 05, 2023 16:05 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS)...